Proteomic profiling reveals Arl6ip-1 as a candidate target in cancer-induced bone pain rat model after oxycodone treatment

•Proteomic profiling of spinal cord tissue of rats with bone cancer pain was obtained by Label-free quantitative proteomics.•Arl6ip-1 may be involved in the formation of hyperalgesia in cancer induced bone pain rats.•Oxycodone may promote Arl6ip-1-Arl6ip-5 formation of heterodimers to participate in analgesic effects. Treatment of cancer-induced bone pain (CIBP) is challenging in clinics. Oxycodone is used to treat CIBP. However, the lack of understanding of the mechanism of CIBP limits the application of oxycodone. In this study, proteomic profiling of oxycodone-treated spinal dorsal cord of rats with CIBP was performed. Briefly, a total of 3519 proteins were identified in the Sham group; 3505 proteins in the CIBP group; and 3530 proteins in the CIBP-OXY treatment group. The 2-fold cut-off value was used as the differential protein standard for abundance reduction or increase (p